The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

09 Apr 2021

Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed... Read more

Oxford Endovascular raises $10m to develop origami engineered device to prevent brain haemorrhage

08 Apr 2021

Funding will support the company to achieve first-in-human data Oxford, UK, 8th April 2021 – Oxford Endovascular, a pioneering British MedTech company and spinout from Oxford University, is developing a treatment for brain aneurysms, that will overcome challenges with existing medical devices. It has just raised $10m in a series A funding round. The funding which was conducted in Pounds Sterling includes a £3m investment from new investors... Read more

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

24 Mar 2021

Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Pierre Legault BAA, MBA, CA, CPA as Chairman of its Board of Directors. Mr. Legault is a renowned industry leader with over 35 years’ international experience in leading biopharmaceutical companies. Neil Weir, Chief Executive Officer of Sitryx, said:... Read more

Vaccitech Completes $168M Series B Financing to Advance 3 Clinical Programs Through Phase 2 Results

17 Mar 2021

Oxford, UK – Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares. The Series B... Read more

Immunometabolism company Sitryx expands into new space at TOSP

08 Mar 2021

Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, March 8 2021 – Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. Sitryx has developed... Read more

News